Proton beam therapy for hepatocellular carcinoma with bile duct invasion
-
Published:2023-08-03
Issue:1
Volume:23
Page:
-
ISSN:1471-230X
-
Container-title:BMC Gastroenterology
-
language:en
-
Short-container-title:BMC Gastroenterol
Author:
Iizumi Takashi,Okumura Toshiyuki,Hasegawa Naoyuki,Ishige Kazunori,Fukuda Kuniaki,Seo Emiko,Makishima Hirokazu,Niitsu Hikaru,Takahashi Mizuki,Sekino Yuta,Takahashi Hiroaki,Takizawa Daichi,Oshiro Yoshiko,Baba Keiichiro,Murakami Motohiro,Saito Takashi,Numajiri Haruko,Mizumoto Masashi,Nakai Kei,Sakurai Hideyuki
Abstract
Abstract
Aim
Hepatocellular carcinoma (HCC) with bile duct invasion (BDI) (BDIHCC) has a poor prognosis. Moreover, due to the paucity of reports, there is no consensus regarding optimal management of this clinical condition yet. The aim of this study was to clarify the efficacy and safety of proton beam therapy (PBT) for BDIHCC.
Methods
Between 2009 and 2018, 15 patients with BDIHCC underwent PBT at our institution. The overall survival (OS), local control (LC), and progression-free survival (PFS) curves were constructed using the Kaplan-Meier method. Toxicities were assessed using the Common Terminology Criteria of Adverse Events version 4.0.
Results
The median follow-up time was 23.4 months (range, 7.9–54.3). The median age was 71 years (range, 58–90 years). Many patients were Child A (n = 8, 53.3%) and most had solitary tumors (n = 11, 73.3%). Additionally, most patients had central type BDI (n = 11, 73%). The median tumor size was 4.0 cm (range, 1.5–8.0 cm). The 1-, 2-, and 3-year OS rates were 80.0%, 58.7% and 40.2%, respectively, and the corresponding LC and PFS rates were 93.3%, 93.3%, and 74.7% and 72.7%, 9.7%, and 0.0%, respectively. Acute grade 1/2 dermatitis (n = 7, 46.7%), and grades 2 (n = 1, 6.7%) and 3 (n = 1, 6.7%) cholangitis were observed. Late toxicities such as grade 3 gastric hemorrhage and pleural effusion were observed. No toxicities of grade 4 or higher were observed.
Conclusions
PBT was feasible with tolerable toxicities for the treatment of BDIHCC.
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference35 articles.
1. Park J, Kim HC, Lee JH, Cho EJ, Kim M, Hur S, et al. Chemoembolisation for hepatocellular carcinoma with bile duct invasion: is preprocedural biliary drainage mandatory? Eur Radiol. 2018;28:1540–50. 2. Ikenaga N, Chijiiwa K, Otani K, Ohuchida J, Uchiyama S, Kondo K. Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion. J Gastrointest Surg. 2009;13:492–7. 3. Oba A, Takahashi S, Kato Y, Gotohda N, Kinoshita T, Shibasaki H, et al. Usefulness of resection for hepatocellular carcinoma with macroscopic bile duct tumor thrombus. Anticancer Res. 2014;34:4367–72. 4. Meng KW, Dong M, Zhang WG, Huang QX. Clinical characteristics and surgical prognosis of hepatocellular carcinoma with bile duct invasion. Gastroenterol Res Pract. 2014;2014:604971. 5. Yang X, Qiu Z, Ran R, Cui L, Luo X, Wu M, et al. Prognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis. Oncol Lett. 2018;16:3593–602.
|
|